Activated clotting time is not a sensitive parameter to monitor anticoagulation with low molecular weight heparin in hemodialysis

Nephron
S GreiberP Schollmeyer

Abstract

To study whether the activated clotting time (ACT) is a sensitive parameter to monitor anticoagulation with low molecular weight heparin (LMWH) during hemodialysis, ACT, polymorphonuclear granulocyte-elastase, and anti-factor Xa activity were studied during 30 dialysis treatments with LMWH (35 IU/kg body weight bolus; 10 IU/h/kg). Twenty treatments were performed with Hemophan, ten with polysulfone dialyzers. No clinically relevant clotting of dialyzers was observed, but minimal fibrin deposition was found more often in the Hemophan group (50 vs. 30%). Despite continuously elevated anti-factor Xa levels (Hemophan 0.49 +/- 0.03, polysulfone 0.62 +/- 0.01 IU/ml), a significant increase of ACT was only demonstrated 10 min after bolus application in the Hemophan group. Elevated polymorphonuclear granulocyte-elastase levels were demonstrated in the Hemophan group but were linked to the presence of minimal fibrin deposits and not to the dialyzer material. We conclude that ACT is not a sensitive parameter to monitor anticoagulation with standard doses of LMWH.

Citations

Aug 9, 2011·Pharmaceutical Research·Abhishek GulatiStephen B Duffull
Dec 14, 2002·Thrombosis Research·Lori Ann LinkinsJeffrey I Weitz
Apr 16, 2002·Artificial Organs·Jürgen Bommer, Michael Schwab
Mar 23, 2004·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Rolf Dario FrankJürgen Floege
Jul 14, 2010·British Journal of Haematology·David J PerrySue Mallett
Jul 27, 2005·Circulation·Shannon M Bates, Jeffrey I Weitz
Apr 4, 2007·Hemodialysis International·Karl-Georg Fischer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Related Papers

Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
James M WilsonKathleen Pinto
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
Rolf Dario FrankJürgen Floege
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
Mark LawrenceGregory J Dehmer
© 2021 Meta ULC. All rights reserved